

# EXHIBIT 9

Page 1

Volume I Pages 1-230

Exhibits 1-25

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY

-----  
IN RE JOHNSON & JOHNSON TALCUM  
POWDER PRODUCTS MARKETING, MDL NO.  
SALES PRACTICES, AND PRODUCTS 16-2738(MAS)(RLS)  
LIABILITY LITIGATION  
-----

VIDEOCONFERENCE DEPOSITION OF  
JOHN GODLESKI, M.D.

Thursday, March 28, 2024, 9:02 a.m.

MARRIOTT BOSTON - QUINCY

1000 Marriott Drive

Quincy, Massachusetts 02169

-----REPORTER: Sonya Lopes, RPR, CSR-----

1 A. Hafnium and yttrium are unusual.

2 Q. Do you know of any products that those  
3 materials are in?

4 A. Not that I know of.

5 Q. With regard to Ms. Newsome, you did not  
6 make an attempt to count or to identify all the  
7 particles in the entirety of the tissue you  
8 received; correct? Let me ask it differently.  
9 That's not a good question.

10 With regard to Ms. Newsome, you did not  
11 make an attempt to look across the entirety of the  
12 tissue you had and identify every particle that's in  
13 that tissue; correct?

14 A. We don't identify -- we don't analyze any  
15 particles that we find on the surface of the tissue  
16 because, even though it's just the edge of the  
17 surface, it very -- has a definite chance of getting  
18 there by contamination in the laboratory. So we  
19 don't analyze that.

20 Sometimes, when there's a lot of tissue to  
21 look at, we'll focus -- we'll draw a map of the  
22 normal ovarian tissue and stay away from the tumor  
23 because -- and especially if it's a serous carcinoma  
24 where we know it has thousands of calcium particles  
25 in there that are all endogenous, it would really